Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | MDM2 over exp TP53 wild-type |
Therapy | AQ-101 |
Indication/Tumor Type | acute lymphoblastic leukemia |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
MDM2 over exp TP53 wild-type | acute lymphoblastic leukemia | sensitive | AQ-101 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, AQ-101 inhibited growth and induced apoptosis in acute lymphocytic leukemia (ALL) cell lines with wild-type TP53 and overexpression of MDM2 in culture, and inhibited development of leukemia in ALL cell line xenograft models (PMID: 29282301). | 29282301 |
PubMed Id | Reference Title | Details |
---|---|---|
(29282301) | Inhibition of MDM2 by a Rhein-Derived Compound AQ-101 Suppresses Cancer Development in SCID Mice. | Full reference... |